Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?

Table 3 Meta-analysis of adverse events

Outcome	Studies	Participants	Statistical method	Effect size	95%CI	P	I2(%)
Anemia	3	240	RR, Fixed	5.32	(2.23-12.66)	0.0002	0
Leukocytopenia	3	240	RR, Random	2.31	(1.08-4.97)	0.03	49
Neutropenia	3	240	RR, Random	1.37	(0.60-3.16)	0.46	78
Thrombocytopenia	3	240	RR, Fixed	2.34	(1.04-5.29)	0.04	0
Anorexia	2	154	RR, Fixed	5.74	(1.05-31.39)	0.04	0
Diarrhea	3	240	RR, Fixed	2.58	(0.51-13.01)	0.25	0
Nausea/vomiting	3	240	RR, Fixed	3.58	(1.32-9.69)	0.01	0
SGPT abnormality	2	154	RR, Fixed	0.99	(0.34-2.88)	0.98	0
Asthenia/Fatigue	2	154	RR, Fixed	3.54	(1.23-10.18)	0.02	29
Weight Loss	2	154	RR, Fixed	4.02	(0.46-35.04)	0.21	0

RR: Relative risk.